• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stephan A. Geier, MD; Ifna Sadri, MD; Johnnes R. Bogner, MD; Frank D. Goebel, MD
Munich, Germany

Arch Ophthalmol. 1994;112(1):20.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Anand et al,¹ in their fine article in the February 1993 issue of the ARCHIVES, describe the efficacy of an intravitreal sustained-release device containing ganciclovir to control CMV retinitis in patients with acquired AIDS. However, these authors did not report on the survival time of their 22 patients after the diagnosis of CMV retinitis.

According to the data provided by Anand et al1^(p225) in Figure 1, we calculated median survival time using the Kaplan-Meier method for the 22 reported patients. Median survival time after diagnosis of CMV retinitis was 5.6 months (Figure).

In contrast, as shown by several studies, median survival time in patients treated with either intravenously administered ganciclovir or foscarnet varies between 8 and more than 12 months.^2,3 Therefore, survival time in patients treated with the intravitreal sustained-release device appears to be shorter compared with patients treated with intravenously applied ganciclovir or foscarnet. In our . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?